ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Jun 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
July 2026
Nuclear Technology
June 2026
Fusion Science and Technology
May 2026
Latest News
Antares achieves zero-power criticality at INL
Leveraging more than $140 million in private capital fundraising, over 322,000 square feet of operational manufacturing space, and multifaceted partnerships with the Departments of Energy and Defense, reactor start-up Antares has become the first company involved in the Reactor Pilot Program to achieve zero-power fueled criticality—a full month ahead of the July 4 deadline set by President Trump’s Executive Order 14301.
This milestone, announced yesterday, was achieved with the company’s Mark-0: a sodium heat-pipe-cooled, TRISO-fueled microreactor. The Mark-0 is a forerunner to the company’s flagship design, which it calls the R1. For Antares, this development represents a key validation of its reactor physics, control systems, and supply chain.
Greg Staack, Yung-Sung Cheng, Yue Zhou, Tom LaBone
Fusion Science and Technology | Volume 71 | Number 4 | May 2017 | Pages 570-574
Technical Note | doi.org/10.1080/15361055.2017.1291041
Articles are hosted by Taylor and Francis Online.
Samples of tritiated LaNi4.15Al0.85 (LANA.85) and 13X zeolite were analyzed to obtain particle size distributions and tritium evolution rates in a simulated lung environment. This information was used to calculate intake-to-dose conversion factors (DCFs), which estimate the committed effective dose (CED) a worker would receive after inhaling either tritiated particulate. The DCFs for tritiated LANA.85 and 13X particulate with a default activity mean aerodynamic diameter (AMAD) of 5 μm were determined to be 1.01E-11 Sv/Bq and 1.11E-11 Sv/Bq, respectively. These results are comparable to that of HTO, 1.8E-11 Sv/Bq, indicating that urine bioassay results can conservatively estimate the dose delivered if the worker was exposed to any mixture of HTO, LANA.85, or 13X.
